Takeda announces its intention to acquire TiGenix

09-Jan-2018 - TiGenix NV confirms that Takeda Pharmaceutical Company Limited has announced its intention to launch a voluntary conditional takeover bid on TiGenix. Takeda intends to acquire 100% of the securities with voting rights or giving access to voting rights of TiGenix not already owned by Takeda or ...

TiGenix opens US headquarters

Operations to be based in Cambridge at heart of Boston area biotech hub

30-Jun-2017 - TiGenix NV announces it has opened an U.S. office in Cambridge, Massachusetts. Establishing U.S. operations is a significant step for TiGenix and will support its strategic goal of developing and commercializing its lead product, Cx601, for the treatment of complex perianal fistulas in Crohn's ...

USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas

09-Apr-2015 - TiGenix NV announced that the United States Patent and Trademark Office (USPTO) has issued US Patent 8,999,709 relating to the use of an adipose-derived stromal cell population in the treatment of fistula. The patent, entitled "Use of adipose tissue-derived stromal stem cells in treating ...

TiGenix and Lonza Sign Agreement for the Manufacture of Stem Cell-based Treatment of Complex Perianal Fistulas in Crohn’s Disease

13-Feb-2015 - Lonza and TiGenix announced an agreement for the supply of TiGenix’s eASC product, Cx601. Under the agreement, Lonza will manufacture material for the Phase 3 trial of Cx601 in the US at Lonza’s cell therapy production facility in Walkersville, Maryland (US). Cx601 is a locally-injected ...

TiGenix starts Phase I trial of Cx611 in severe sepsis

11-Dec-2014 - TiGenix NV announced that the first subject has been entered into its Phase I trial of Cx611 in severe sepsis.Cx611 is an intravenously-administered product of allogeneic expanded adipose-derived stem cells (eASC's). The product will enter Phase II of clinical development for early rheumatoid ...

TiGenix's new European production facility obtains EMA approval for commercial production of ChondroCelect

26-Sep-2012 - TiGenix announced that after the successful cGMP inspection by the Dutch authorities earlier this year, it has now obtained the crucial approval from the European Medicines Agency (EMA) for the production of ChondroCelect, the company's commercial cell therapy product for cartilage repair in the ...

TiGenix appoints chairman and member of board of directors

21-Sep-2012 - TiGenix announced that the Company has appointed JeanStéphenne as independent director and new chairman of the Company's board of directors, and Russell Greig as independent director, in replacement of Koenraad Debackere and Mounia Chaoui-Roulleau, who resigned from the board. Former chairman ...

TiGenix reports positive results of Cx621 Phase I

03-Jul-2012 - TiGenix announced that it has successfully completed the company's Phase I clinical trial to assess the safety of intra-lymphatic administration of its expanded adipose stem cells product (Cx621). Cx621 aims to capitalize on the benefits of TiGenix's proprietary approach of intra-lymphatic ...

TiGenix obtains manufacturing license for European production facility

24-Apr-2012 - TiGenix announced that further to the cGMP inspection by the Dutch authorities it has obtained the manufacturing authorization for human medicinal products for its European manufacturing plant in Sittard-Geleen in the Netherlands."I'd like to commend our manufacturing team responsible for ...

TiGenix rheumatoid arthritis Phase IIa study successfully passes last safety hurdle

23-Apr-2012 - TiGenix announced that upon review of the safety data of the first three patients of the third cohort of the company's Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit and dose the remaining patients of ...